Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks

Emergent BioSolutions ($EBS) just launched a military-grade intramuscular autoinjector device for self-administration of antidotes in the case of a chemical weapons attack. The device aims to provide militaries across the world with medical countermeasures to biological and chemicals threats. It has a needle that can penetrate not just skin, but soldiers' protective gear. The rollout of Emergard won't include the U.S., where the company intends to seek FDA approval. More from FierceMedicalDevices

Suggested Articles

Xeris bucked pandemic trends with the July launch of its Gvoke HypoPen for hypoglycemia, boosting glucagon prescriptions across the board.

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.